My ePortfolio Register   

Advances in hormone sensitive prostate cancer and castration resistance management

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.10.17
Views: 1865

Prof Heather Payne, Dr Gero Kramer, Prof Maria De Santis and Prof Kurt Miller

The panel summarise the key discussion points from the 2-day interactive meeting; with the key themes focusing around the recent advances in hormone sensitive prostate cancer and castration resistance management.

Prof De Santis summaries data from 3 key docetaxel trials over the last few years and the most recent pooled meta-analysis data.

The panel raise questions over the suggested categorisation of patients into low/high risk disease and debate whether following such specific criteria is too restrictive given the improvement in overall survival with the addition of docetaxel over ADT.

Prof Kramer highlights the key differentiating factors from Latitude and Stampede (both trials having met their primary and secondary endpoints) and discusses the inclusion criteria of high risk patients into both trials.

The addition of Abiraterone acetate to ADT as a 1L treatment is potentially practice changing (pending reimbursement) and could offer an improvement in side effects and quality of life to patients over 1L chemotherapy use.

Prof Miller shares his views on the data and the key considerations for future decision making.

The group then discuss some general practical considerations of managing prostate cancer patients including; measuring patients bone density, cognitive assessments and advice around sexual function.

They note that advice and opinion will differ throughout practice but share some of their own thoughts on these topics.

The evolution in imaging technology was highlighted as a rapidly progressing field for prostate cancer management with the expectations that it will assist with further patient stratification.

The panel briefly touch on the treatment of elderly patients and concur that assessments for treatment should be based on performance status, biologic age and geriatric assessments (G8 tool was mentioned as part of the EU guidelines).

They comment that treatment approaches for patients with oligometastases remains to be an area of unmet need with inconclusive evidence and requires further research.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence